Figure 2. All-Cause and Prostate Cancer Survival Probabilities in Men Exposed and Unexposed to 5α-Reductase Inhibitors (5-ARIs) at Study Start.

Adjusted for age, prostate-specific antigen levels, previous negative biopsy, family history of prostate cancer, education, civil status, Charlson Comorbidity Index scores, and year of study entry. Solid lines indicate adjusted survival probabilities; dashed lines, 95% pointwise CIs.